Podcast episode 143 (in German)
Alpha-GPC & citicoline – two studies from Korea, two directions
November 20, 2026
On the nootropics shelf, two choline sources stand side by side, and from Korea come two large analyses pointing in opposite directions. Add to that a placebo trial on whose outcome the manufacturers themselves have bet money, and the question of what users actually feel.
What it is about
Alpha-GPC and citicoline supply choline, the building block of acetylcholine, which plays a role in attention and memory in the brain. The messenger was discovered by the Graz pharmacologist Otto Loewi using 2 frog hearts, and in 1936 this earned the Nobel Prize. In Korea, Alpha-GPC is a prescription drug: one analysis saw more strokes in people who were prescribed it, a second fewer transitions to dementia. Users from nootropics forums mainly report a little more drive and a clearer head; these are self-reports without placebo, but small studies in healthy people ask exactly about this. In the end there is no verdict but a weighing: a somewhat clearer afternoon on one side, and on the other the question of whether one belongs to the group in which the warning signal was measured.
Key points
- A user report, not evidence of efficacy: in a 2014 survey from 2 nootropics forums, citicoline received 5.37 and Alpha-GPC 5.07 out of 10 points, the simple choline salt, used by the author as a placebo benchmark, 3.7.
- Among 12 million people aged 50 and over in Korea, those prescribed Alpha-GPC had a 46 percent higher risk of stroke over 9 years, 43 percent in the strict matched comparison.
- A second analysis from the same insurer with a little over 500,000 people with mild cognitive impairment found in 2025 that under Alpha-GPC Alzheimer’s was around 10 percent less frequent and vascular dementia around 17 percent less frequent.
- In June 2020 the Korean drug agency demanded new evidence; the manufacturers pledged to repay 20 percent of insurance prescriptions if the indication were dropped, and one set aside around 107 billion won for this.
- According to the Korean press, the 48-week placebo trials missed their primary goal; with per-protocol intake, Alpha-GPC was ahead at 67.8 versus 60.1 percent, just short of the usual threshold for chance.
- In 2012, in a Lancet study with 2,298 people after acute stroke, citicoline showed no benefit, odds ratio 1.03, but also no accumulation of side effects.
- In healthy people there are small studies with isolated hits: 39 people in Japan had more motivation in the evening after 2 weeks of Alpha-GPC, and 100 people aged 50 and over had better memory on secondary endpoints after 12 weeks of citicoline.
Where the data stop
Both Korean analyses are observational. Those prescribed Alpha-GPC were on average 68 rather than just under 62 years old and sicker, and anyone complaining about their memory may already have calcified blood vessels. The second study also names a bias in the timing of intake itself. Observation against observation results in an open question, not a verdict. The results of the placebo trials are so far known only from the Korean press; as of September 2026, neither a publication nor a decision by the agency was available.
The studies in healthy people are small and mostly close to the manufacturer: the author of the study with 20 trained men advises the manufacturer, the citicoline study was paid for by the manufacturer, and there are also studies with no effect at all. The forum reports come from 15 and 19 people per form and agree only in direction. Anyone over 50, with high blood pressure or atrial fibrillation, or who has already had a stroke, discusses taking it with a doctor beforehand.
Listen (in German)
Listen on Spotify Listen on Apple Podcasts Listen on Amazon Music
Published on November 20, 2026.
The topic in the database
- Highly bioavailable choline source. Increases acetylcholine in the brain – untested in healthy people, plus a stroke signal from a large cohort.Alpha-GPC
All episodes in the app (German)
Information only, not medical advice and not a usage or dosage recommendation. Prescription-only and unapproved substances belong in the hands of a physician. Last updated: 2026-09-25.